Healius (ASX:HLS) released its FY26 full-year results on 19 August 2026, reporting a significant improvement in underlying profitability.

Underlying group Revenue increased 2.1% to $1.373 billion, while underlying EBITDA rose 8.1% to $258.6 million. Underlying EBIT increased 76.6% to $30.2 million, compared with $17.1 million a year earlier.

On a statutory basis, however, the company reported an EBIT loss of $328.9 million and a net loss after tax of $415.6 million. The statutory result was heavily affected by a $332.0 million non-cash Goodwill Impairment relating to the pathology business.

No final Dividend was declared.

The results showed that Healius's cost-reduction and pricing initiatives are beginning to improve underlying earnings, although management also indicated that its previous medium-term Margin target has been pushed back by approximately 18 months.

Company and asset background

Healius operates community pathology and pathology collection services across Australia through brands including Laverty Pathology, Dorevitch Pathology and QML Pathology.

The group also owns Agilex Biolabs, a contract research and bioanalytical laboratory Business serving pharmaceutical and biotechnology clients.

Healius sold its Lumus Imaging diagnostic-imaging business to Affinity Equity Partners in 2024 as part of an effort to reduce Debt and simplify the company around its pathology operations.

In 2026, Healius finalised a new national framework covering pathology service arrangements with hospitals operated by Ramsay Health Care.

The company has also been reviewing its asset portfolio, including strategic Options for Agilex Biolabs.

Financial and operational picture

For FY27, management expects EBIT to be broadly in line with consensus expectations of approximately $39.7 million. However, the company now expects its mid-to-high single-digit EBIT margin target to be reached around December 2028, approximately 18 months later than previously indicated.

The bull case

The turnaround case is supported by measurable improvements in underlying earnings.

Underlying EBIT increased sharply, pathology margins strengthened during the second half and the company's cost-reduction programme continues to deliver savings.

Agilex Biolabs is also growing strongly and could potentially unlock additional value if the strategic review results in a sale or other transaction.

Although the Balance Sheet now carries net debt, gearing remains relatively modest against the company's banking covenants. This provides some capacity for continued Investment in areas such as digital pathology and automation.

A successful strategic review could also leave Healius with a more focused pathology business while potentially generating proceeds that could be used to reduce debt or support other capital-management initiatives.

The risks

Pathology volumes declined 1.3% during FY26, meaning revenue growth depended partly on higher fees rather than increased testing activity. Sustaining this approach could become more difficult if pricing conditions change.

The $332 million goodwill impairment also highlights reduced expectations around the future cash-generating capacity of parts of the pathology business.

The delay to the medium-term margin target raises questions about the pace and consistency of the turnaround. Further cost pressures or weaker operating conditions could push the recovery timeline out again.

The move from net cash to net debt also reduces financial flexibility.

Healius remains exposed to government healthcare policy, Medicare funding arrangements and changes to pathology reimbursement settings, all of which can affect the Economics of its core business.

What to watch next

The outcome of Healius's strategic review will be an important development, particularly whether Agilex Biolabs is sold and the value generated from any transaction.

Investors will also be watching progress against FY27 EBIT expectations of approximately $39.7 million.

Quarterly updates on pathology testing volumes, fee growth and margins should provide a clearer picture of whether the second-half improvement is sustainable.

Further detail on the pathway toward the revised December 2028 margin target will also be important.

The implementation of the new Ramsay Health Care pathology services framework, along with any debt-management or capital-allocation announcements, will remain relevant to the company's outlook.

Conclusion

Healius has delivered a meaningful improvement in underlying earnings, with EBIT increasing sharply as cost savings and pricing initiatives begin to flow through.

However, the turnaround remains incomplete. Pathology volumes are still under pressure, the company has moved into a net debt position and its medium-term margin target has been pushed back.

The next phase of the story will depend on whether management can sustain the second-half margin improvement, deliver its FY27 Earnings expectations and use the strategic asset review to strengthen the group's financial and operational position.